The total return over the past 12 months is -5.13% vs. +16.94% for the S&P 500. So far it's up -16.18% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (5.13%) | +2.22% | +4.61% | +17.07% | N/A | N/A |
| Total Return CAGR | (5.13%) | +2.22% | +4.61% | +17.07% | N/A | N/A |
| Revenue CAGR | (100.00%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Xenon Pharmaceuticals Inc. (XENE)
| Year | Start price | End price | XENE Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $44.82 | $37.57 | (16.18%) | +14.51% | (30.69%) |
| 2025 | $39.20 | $44.82 | +14.34% | +17.72% | (3.38%) |
| 2024 | $46.06 | $39.20 | (14.89%) | +24.89% | (39.78%) |
| 2023 | $39.43 | $46.06 | +16.81% | +26.19% | (9.38%) |
| 2022 | $31.24 | $39.43 | +26.22% | (18.17%) | +44.39% |
| 2021 | $15.38 | $31.24 | +103.12% | +28.74% | +74.38% |
| 2020 | $13.11 | $15.38 | +17.32% | +18.37% | (1.05%) |
| 2019 | $6.31 | $13.11 | +107.77% | +31.22% | +76.55% |
| 2018 | $2.83 | $6.31 | +122.97% | (4.56%) | +127.53% |
| 2017 | $7.70 | $2.83 | (63.25%) | +21.70% | (84.95%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
